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Abstract
Background:  Certain strains of an obligate parasite of the human upper respiratory tract,
nontypeable Haemophilus influenzae (NTHi), can cause invasive diseases such as septicemia and
meningitis, as well as chronic mucosal infections such as otitis media. To do this, the organism must
invade and survive within both epithelial and endothelial cells. We have identified a facilitator of
NTHi survival inside human cells, virulence-associated protein D (vapDHi, encoded by gene
HI0450). Both vapDHi and a flanking gene, HI0451, exhibit the genetic and physical characteristics
of a toxin/antitoxin (TA) locus, with VapDHi serving as the toxin moiety and HI0451 as the antitoxin.
We propose the name VapXHi for the HI0451 antitoxin protein. Originally identified on plasmids,
TA loci have been found on the chromosomes of a number of bacterial pathogens, and have been
implicated in the control of translation during stressful conditions. Translation arrest would
enhance survival within human cells and facilitate persistent or chronic mucosal infections.
Results:  Isogenic mutants in vapDHi were attenuated for survival inside human respiratory
epithelial cells (NCI-H292) and human brain microvascular endothelial cells (HBMEC), the in vitro
models of mucosal infection and the blood-brain barrier, respectively. Transcomplementation with
a vapDHi allele restored wild-type NTHi survival within both cell lines. A PCR survey of 59 H.
influenzae strains isolated from various anatomical sites determined the presence of a vapDHiallele
in 100% of strains. Two isoforms of the gene were identified in this population; one that was 91
residues in length, and another that was truncated to 45 amino acids due to an in-frame deletion.
The truncated allele failed to transcomplement the NTHi vapDHi survival defect in HBMEC.
Subunits of full-length VapDHi homodimerized, but subunits of the truncated protein did not.
However, truncated protein subunits did interact with full-length subunits, and this interaction
resulted in a dominant-negative phenotype. Although Escherichia coli does not contain a homologue
of either vapDHi or vapXHi, overexpression of the VapDHi toxin in trans resulted in E. coli cell growth
arrest. This arrest could be rescued by providing the VapXHi antitoxin on a compatible plasmid.
Conclusion: We conclude that vapDHi and vapXHi may constitute a H. influenzae TA locus that
functions to enhance NTHi survival within human epithelial and endothelial cells.
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Background
Culturable  Haemophilus influenzae are acquired in the
nasopharynx shortly after birth, and are thought to persist
throughout life. H. influenzae adheres to and penetrates
into and between cultured human respiratory epithelial
cells, a mechanism that may contribute to its persistence
in chronic obstructive pulmonary disease (COPD) and
cystic fibrosis (CF) patients [1,2]. H. influenzae can be
found in the respiratory tracts of these patients even after
they have undergone antibiotic treatment [3]. As well,
COPD sputum cultures can be sterile, while H. influenzae
can still be isolated from the subepithelial matrix [4].
Finally, we have found in a recent in vivo study that H.
influenzae can persist in a human bronchiolar xenograft
for at least three weeks [5]. This suggests that the organism
can survive and persist in protected biological
compartment(s).
The ability of H. influenzae to survive antibiotic treatment
and reappear when growth is favorable may be responsi-
ble for the reseeding of the middle ear observed in chronic
otitis media. Often, middle ear fluid from children pre-
senting with otitis media with effusion are sterile when
cultured, but PCR analysis of the fluid has determined the
presence of H. influenzae [6]. Further, RT-PCR studies of
this sterile fluid have shown the presence of bacterial
mRNA, confirming that the bacteria are alive and persist-
ing in a viable but nonreplicative state [7].
Persistence was investigated in vitro using a NTHi strain
that was susceptible to β-lactam antibiotics. This strain
was allowed to invade a human respiratory epithelial cell
monolayer for 24 hours, which was subsequently treated
with a 4 hour incubation in 10 × MIC concentrations of
the β-lactam antibiotics ampicillin, imipenem, cefuroxim,
amoxycillin/clavulanic acid, or cephalothin. The antibiot-
ics killed all the extracellular bacteria, but none of the
intra- or paracellular bacteria, suggesting that the organ-
ism was not replicating inside or between the epithelial
cells [8]. Non-replicating bacteria are not susceptible to
the cidal action of β-lactam and aminoglycoside
antibiotics.
During a study aimed at identifying genes associated with
virulence in pathogenic strains of the Gram-negative,
strict anaerobe Dichelobacter nodosus, the causative agent
of ovine footrot, Katz et al. [9] reported the discovery of a
novel area of the chromosome that hybridized to all viru-
lent strains tested, but to only 23% of the avirulent strains
studied. They designated the four genes found on this
fragment as vapA-D, for virulence-associated  proteins.
Homologues of these genes appear on the chromosomes
and plasmids of a number of pathogenic microorganisms,
including  Neisseria gonorrhoeae,  Helicobacter pylori,
Reimerella anatipestifer and  Actinobacillus actinomycetem-
comitans. The chromosome of H. influenzae strain Rd
KW20 (hereinafter referred to as strain Rd) contains vapA,
vapBC, and vapD homologues, with one pair, vapBC, in
duplicate. The genome organization of the vap genes in H.
influenzae differs from that of D. nodosus, in that vapAHi
(HI1250) is preceded by a conserved hypothetical pro-
tein, HI1251, and both genes are likely transcribed as an
operon. As well, vapDHi is flanked by a gene encoding
another conserved hypothetical protein, HI0451 (which
we have named vapXHi), again in an apparent operon con-
figuration (8 nucleotides separate HI0450 and HI0451).
To determine if the vap homologues played a role in the
persistence of NTHi, we chose vapDHi (HI0450) for further
study, since this protein was found in a proteomic survey
to be expressed in the soluble fraction of strain Rd [10].
VapDHi is 40% identical and 67% similar to the Dichelo-
bacter VapD and belongs to the Cluster of Orthologous
Groups (COG) 3309 and Pfam 04605, termed the "N-ter-
minal conserved domain of VapD".
Results
Mutation of vapDHi results in attenuated survival in 
human endothelial cells
When the Rd vapDHi mutant strain was used to invade the
in vitro model of the blood-brain barrier, human brain
microvascular endothelial cells (HBMEC) in 12-well
plates, the amount of gentamicin-resistant bacteria recov-
ered from the monolayer after three hours declined to
approximately 60% of wild type levels, an average of 2.2
× 103 CFU/ml for the wild-type strain Rd versus 1.3 × 103
CFU/ml for the Rd vapDHi mutant (n = 3 (number of inde-
pendent assays performed in at least duplicate); P < 0.05,
Student's t test). No significant difference was observed
between the wild type and vapDHi mutant in adherence to
the human cell monolayers: the average number of cell-
associated bacteria (both adherent and invaded) recov-
ered for strain Rd was 1.5 × 105 CFU/ml and 1.8 × 105
CFU/ml for the Rd vapDHi mutant (n = 3; P > 0.05).
To determine if the phenotype of attenuated survival
observed in the Rd vapDHi mutant was a general phenom-
enon and not restricted to strain Rd, another isogenic pair
was constructed and analyzed using a different strain,
R3001. R3001 is a bronchoalveolar lavage isolate from a
pediatric cystic fibrosis patient, and is considered invasive
since it came from a normally sterile site [5]. The average
number of gentamicin-resistant bacteria recovered from
HBMEC monolayers was 1.2 × 105 CFU/ml for the parent
strain R3001 versus 7.1 × 104 CFU/ml for the R3001 vap-
DHi mutant (n = 3; P < 0.05). Although the absolute num-
bers of bacteria recovered were higher with strain R3001
than with Rd (as is often observed with invasive isolates),
the attenuation of survival inside the HBMEC monolayer
of ≤ 60% observed in the strain with a vapDHi mutation
was maintained. There was no significant differenceBMC Microbiology 2004, 4:30 http://www.biomedcentral.com/1471-2180/4/30
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between the wild-type R3001 and the R3001 vapDHi
mutant in adherence to the monolayer: the average num-
bers of cell-associated bacteria recovered for strain R3001
were 1.7 × 107 CFU/ml versus 1.3 × 107 CFU/ml for R3001
vapDHi (n = 4; P > 0.05). Unlike Rd, strain R3001 carries
the high molecular weight (HMW) adhesins, which may
account for its more efficient adherence to the HBMEC
monolayer [11]. No significant difference in the growth
rates of either of the vapDHi mutants versus their cognate
parent strains were observed, whether grown in bacterio-
logical media (sBHI broth) or on HBMEC or NCI-H292
monolayers (data not shown).
Mutation of vapDHi results in diminished long-term 
survival inside human respiratory epithelial cells
To determine if the vapDHi mutation would affect the abil-
ity of H. influenzae to survive inside human respiratory
epithelial cells over a longer period of time, 18-hour inva-
sion assays were performed using NCI-H292 cells. The
number of gentamicin-resistant bacteria recovered from
the NCI-H292 monolayer after 18 hours for the parent
strain Rd was an average of 6.4 × 104 CFU/ml versus 3.2 ×
104 CFU/ml for the Rd vapDHi mutant (n = 3; P < 0.05).
This represents a 50% reduction in survival of the vapDHi
mutant within epithelial cells as compared to the parent
strain, more attenuation than was seen for the three hour
assays.
Transcomplementation of Rd vapDHi
The vapDHi locus from strain R3001 was cloned into the
mobilizable broad host range plasmid pDD515, creating
pDD564, and conjugally transferred into the Rd vapDHi
mutant (Table 1). The plasmid pDD515 is a derivative of
the IncQ plasmid RSF1010 and has an approximate copy
number of 12 per chromosome in H. influenzae [12]. The
survival inside HBMEC of strain Rd (pDD515) was within
5% of strain Rd without the vector in identical assays
(data not shown). Carrying a vapDHi locus in trans restored
wild-type survival of Rd vapDHi (pDD564) within HBMEC
monolayers. The amount of gentamicin-resistant bacteria
recovered from the endothelial cell monolayer after a
three hour invasion assay was an average of 8.0 × 102
CFU/ml for Rd (pDD515), the vector control, and 7.6 ×
102 CFU/ml for the mutant strain that carried the wild-
type vapDHi allele in trans, Rd vapDHi (pDD564) (n = 3; P
> 0.05), indicating that there was no significant difference
in the survival inside HBMEC monolayers of the wild type
strain versus the transcomplemented strain. These data
confirm that the phenotype of attenuated survival was due
to the interruption in vapDHi and not to polar effects.
The R3001 vapDHi mutant mirrored the survival defect
seen with the Rd vapDHi mutant, at approximately 60% of
wild-type R3001 levels. However, attempts to conjugate
the mobilizable broad host range plasmid carrying the
vapDHi locus, pDD564, into strain R3001 for transcomple-
mentation studies failed repeatedly. This clinical isolate
likely has a plasmid or an origin of replication of the same
incompatibility group incorporated into its chromosome
and therefore will not maintain the broad host range plas-
mid for transcomplementation [13].
Reverse-transcriptase PCR of bacteria from human cell 
monolayers
To determine if the vapDHi locus was transcribed during
contact with a human cell monolayer, total RNA was iso-
lated from the wild-type strain Rd recovered after 18 hours
on HBMEC or NCI-H292 monolayers and was used as the
template for RT-PCR. Figure 1 shows the 153 bp band
amplified with the vapDHi-specific primers, with a molec-
ular weight marker in lane A. The template for lane B is Rd
RNA from HBMEC endothelial cell monolayers, lane C is
its cognate negative control, with no reverse transcriptase
added to the RNA prior to PCR amplification. Lane D
shows the results using Rd RNA from NCI-H292 epithelial
cell monolayers; lane E is its cognate negative control. The
Agarose gel of RT-PCR products Figure 1
Agarose gel of RT-PCR products. Reverse-transcriptase 
PCR (RT-PCR) of total RNA isolated from wild-type strain 
Rd after 18 hours of contact with either HBMEC (human 
endothelial cell) or NCI-H292 (human epithelial cell) monol-
ayers. Lane A: Molecular weight marker (Promega 1 Kb lad-
der); lane B: RNA from Rd on HBMEC monolayers; lane C: 
Negative control for lane B (no reverse transcriptase added 
prior to PCR); lane D: RNA from Rd on NCI-H292 monolay-
ers; lane E: Negative control for lane D (no reverse tran-
scriptase added prior to PCR).
vapDHi
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vapDHilocus is transcribed when strain Rd is in contact
with either human epithelial or endothelial cell
monolayers.
PCR survey of vapDHi
In order to estimate the carriage rate of vapDHi among the
highly heterologous NTHi strains, a PCR survey of 59
commensal and disease-associated strains was undertaken
(Table 2). The vapHI primer set was used. In Rd, these
primers amplify a 769 bp PCR product that includes the
full-length vapDHi gene.
Purified chromosomal DNA preparations from 53 ran-
domly-chosen NTHi strains and one each of the six capsu-
lar serotypes of H. influenzae (types a through f) from the
American Type Culture Collection (ATCC) reference
strains described in Table 2 were subjected to PCR with
the vapHI forward and reverse primers. The NTHi strains
included nasopharyngeal, blood, CSF, middle ear, tra-
cheal aspirate, and sputum isolates. A PCR product was
amplified in 100% of the strains. All of the ATCC encap-
sulated reference strains and Rd displayed a full-length
vapDHiallele. Ninety-three percent of the nasopharyngeal
strains carried a full-length allele, as did 71% of the blood
and CSF isolates, and 50% of the middle ear, tracheal
aspirate, and sputum isolates. Overall, only ten strains of
the 59 included in the study displayed a truncated gene.
Sequencing of the truncated vapDHi allele
To study the truncated vapDHi in more detail, five out of
the ten alleles that represented the smaller isoform of vap-
DHi from the PCR survey were sequenced on both strands.
It was found that, in all cases, the gene had undergone a
deletion event that had left the protein in frame, but miss-
ing 46 amino acids from the interior of the protein, result-
ing in a 45 amino acid protein rather than the full-length
91 amino acid protein (Figure 2). This corresponds to the
loss of Rd genome coordinates 473123 to 473263. In
addition, all of the smaller alleles had an aspartate residue
inserted at position #7 as compared to Rd, which has a
leucine at that position. The significance of this is unclear,
as the full-length R3001 vapDHi allele, which did trans-
complement the Rd vapDHi mutant, also has an aspartic
acid inserted at the same position, resulting in a 91 amino
acid protein. Interestingly, the VapD homologues from N.
gonorrhoeae, H. pylori and A. actinomycetemcomitans, as well
as VapD in D. nodosus, all have an aspartate at that posi-
tion. Rd appears to be the only H. influenzae strain studied
which lacks that particular residue.
Full-length VapDHi homodimerizes
Using an E. coli-based protein-protein interaction system
that is dependent upon the DNA-binding domain (DBD)
of LexA, homodimerization of identical protein subunits
can be quantitated [14,15]. In this system, protein-protein
interactions result in a LexA dimer that is active as a repres-
sor, and consequently, the beta-galactosidase activity of
Table 1: Plasmids and E. coli strains used in this study.
Plasmid Description Reference
pBluescript Cloning vector, ApR Stratagene
pDD515 RSF1010 ori; a mobilizable broad host range vector, CmR 12
pDD559 pSR658 with vapDHi in frame with wild-type LexA DNA-binding domain (DBD) This work
pDD560 pTrcHisA with vapDHi This work
pDD561 pSR659 with vapDHi in frame with mutant LexA DBD This work
pDD562 pBluescript with vapDHi region This work
pDD563 pDD652 with an aph(3')II gene interrupting vapDHi This work
pDD564 pDD515 with a full-length vapDHi region for transcomplementation This work
pDD577 pSR658 with a truncated vapDHi in frame with the wild-type LexA DBD This work
pDD594 pDD515 with a truncated vapDHi region for transcomplementation This work
pDD672 pDD515 with the vapXHi antitoxin for rescue This work
pSR658 Wild-type LexA DBD fusion vector, TcR 15
pSR659 Mutant LexA DBD fusion vector, ApR 15
pTrcHisA Cloning vector, ApR Invitrogen
Strain Description Source
DD12 Conjugal host strain 12
DH5α Cloning strain Promega
SU101 Homodimerization reporter strain 14
SU202 Heterodimerization reporter strain 14BMC Microbiology 2004, 4:30 http://www.biomedcentral.com/1471-2180/4/30
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Multiple sequence alignment of truncated VapDHi proteins Figure 2
Multiple sequence alignment of truncated VapDHi proteins. Wild type full-length VapDHi protein sequence from strain 
Rd is included for comparison. R296: middle ear isolate; R3122: blood isolate; R2751: sputum isolate; R2866: blood isolate; 
R3270: nasopharynx isolate.
Table 2: H. influenzae strains used in this study.
Strain* Description Type vapDHiallele† Prevalence
R538 ATCC #9795 b WT 100%
R539 ATCC #9006 a WT
R540 ATCC #9007 c WT
R541 ATCC #9008 d WT
R542 ATCC #8142 e WT
R543 ATCC #9833 f WT
R652, R3460*, R3539*, R3540*, R3541*, R3542* Rd NTHi WT
Strain Anatomical site‡ Type vapDHiallele Prevalence
C378, C483, C1591, C1607, R1624, R1625, R1627, R1632, R2754, R3254, 
R3256, R3258, R3259, R3262, R3264, R3265, R3266, R3267, R3268, 
R3269, R3271, R3273, R3274, R3276. R3277, R3282, R3283, R3285
Nasopharynx NTHi WT 93% (28/30)
R3257, R3270 TV 7%
R2752, R3001, R3027, R3157, R3543* Sputum/Tracheal Aspirate/Ear NTHi WT 50% (4/8)
R296, R2751, R2846, R3151 TV 50%
C432, R228, R2777, R3168, R3252, R3278, R3279, R3280, R3330, R3331 Blood/CSF NTHi WT 71% (10/14)
R2866, R3122, R3164, R3169 TV 29%
*: Asterisk denotes derivative strains, i.e. R3460 is strain R652 carrying the vector pDD515. The marked strains are not included in computing the 
incidence of the wild-type vapDHi allele versus the truncated allele. Independent strains are not marked with an asterisk. †: Type of vapDHi allele: WT 
= wild type (91 amino acids); TV = truncated version (45 amino acids). ‡: Site from which strains were isolated.
1            15 16          30 31            45
R296 MYAIAFDLVVKDTQD YHPKGVQEAYTDIR- --------------- 29 
R3122 MYAIAFDLVVKDTQD YHPKGVQEAYTDIR- --------------- 29
R2751 MYAIAFDLVVKDTQD YHPKGVQEAYTDIR- --------------- 29
R2866 MYAIAFDLVVKGTQD YHPKGVQQAYTDIG- --------------- 29
R3270 MYAIAFDLVVKDTQD YHPKGVQQAYTDIG- --------------- 29
Rd MYAIAF-LVVKDTQD YHPKGVQQAYTDIGA VLAKFGFVRTQGSLY  44
46           60 61           75 76               91
R296 --------------- --------------- AFRIEQWSDFTDFIRN 45
R3122 --------------- --------------- AFRIEQWSDFTDFIRN 45
R2751 --------------- --------------- AFRIEQWSDFTDFIRN 45
R2866 --------------- --------------- AFRIEQWSDFTDFIRN 45
R3270 --------------- --------------- AFLIEQWSDFTDFIRN 45
Rd  INMNEDMANLFQAMN ALKQAWISQSVRDIR AFRIEQWSDFTDFIRN 90BMC Microbiology 2004, 4:30 http://www.biomedcentral.com/1471-2180/4/30
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the reporter strain (SU101) diminishes. Full-length Vap-
DHi from strain R3001 was ligated to the DBD of LexA in
plasmid pDD559 and the clones were analyzed on Mac-
Conkey agar with lactose. If there was no homodimeriza-
tion of the LexA::VapDHi  fusion protein, the colonies
appeared red on MacConkey agar, as the native level of
beta-galactosidase expression in the reporter strain was
not inhibited. If the subunits interacted, the colonies
appeared pale on MacConkey, as the engineered LexA
operator controlling the lacZ  reporter gene had been
repressed by a homodimer of the LexA fusion protein.
This repression was quantitated by beta-galactosidase
activity assays. Each measurement is the mean of at least
three experiments performed in triplicate.
It was found that VapDHi interacted strongly with itself.
The beta-galactosidase activity of the reporter strain
SU101 carrying the vector control (pSR658) was an aver-
age of 975 (± 29) Miller units, and the activity of SU101
with the LexA::VapDHi fusion (pDD559) was an average of
16 (± 1) Miller units, indicating strong interaction. Full-
length VapDHi forms homodimers in vivo. This protein
may also form higher-order multimers, since this would
result in a number of dimeric forms being available to act
as a repressor of lacZ transcription in the reporter strain.
Truncated VapDHi does not homodimerize, but interacts 
with full-length VapDHi
Homodimerization assays with the small allele revealed
that the subunits of the truncated VapDHi did not interact
efficiently. The vector control for the homodimerization
assays SU101 (pSR658) yielded 1490 (± 31) Miller units,
and SU101 carrying the LexA fusion to the truncated Vap-
DHi protein from strain R2866 (pDD577) displayed 1357
(± 54) Miller units of beta-galactosidase activity, showing
little repression in this system.
Since the wild-type VapDHi  subunits homodimerized
strongly but the truncated subunits did not, the truncated
subunit and the full-length subunit were examined for
interaction in heterodimerization assays. In the reporter
strain SU202, a LexA operator with a mutated half-site was
engineered upstream of the lacZ gene. This strain was then
transformed with two compatible plasmids, one that car-
ried a fusion of the truncated VapDHi with a wild-type
LexA DBD, and one that carried the full-length VapDHi
fusion to a mutated LexA DBD that only recognized the
mutated LexA operator half-site in SU202 [15]. If a het-
erodimer of a truncated subunit and a full-length subunit
was formed, a functional LexA repressor could recognize
the hybrid operator and repress transcription of lacZ. It
was determined that the truncated and full-length subu-
nits could interact with each other. The vector control for
the heterodimerization assays (SU202 with pSR658 and
pSR659) yielded 1855 ± 196 Miller units, and SU202 car-
rying the LexA fusion to the truncated VapDHi protein
from strain R2866, pDD577, coupled with the mutated
LexA DBD fusion to the full-length VapDHi protein from
strain R3001, pDD561, resulted in 792 ± 19 Miller units
of beta-galactosidase activity, showing that the truncated
subunit did heterodimerize with the full-length VapDHi
subunit.
Truncated VapDHi does not transcomplement the mutant 
and has a dominant-negative effect in the wild-type strain
To investigate whether the truncated VapDHi  protein
could transcomplement a mutation in the full-length
gene, the truncated locus from strain R2866 was cloned
into the mobilizable broad host range vector pDD515,
creating pDD594, and conjugally transferred into the Rd
vapDHi mutant strain. Three-hour survival assays using
HBMEC monolayers were performed, and the number of
gentamicin-resistant bacteria recovered from the
monolayer was an average of 5.6 × 102 CFU/ml for Rd
(pDD515), the vector control, versus 1.9 × 102 CFU/ml for
Rd  vapDHi(pDD594) (n = 3; P < 0.005). Survival in
HBMEC by the mutant strain did not increase to wild-type
levels, as was the case with the Rd vapDHi  mutant
transcomplemented with a full-length vapDHi allele on
pDD564.
Since subunits of the full-length VapDHi and the truncated
protein interacted, the plasmid pDD594 carrying the trun-
cated allele was conjugally transferred into wild-type
strain Rd to determine whether expression of the small
protein would interfere with the function of the wild-type
VapDHi protein. The strain was used in three-hour assays
of HBMEC monolayers, and it was found that Rd
(pDD594) was attenuated in human cell survival as com-
pared to Rd (pDD515), the wild-type strain carrying the
vector without an insert. The average number of gen-
tamicin-resistant bacteria recovered from the monolayer
for Rd (pDD515), the vector control, was 5.7 × 102 CFU/
ml versus 1.8 × 102 CFU/ml for Rd (pDD594) (n = 3; P <
0.005). The in trans expression of a truncated vapDHi allele
in the wild-type strain Rd resulted in a dominant-negative
effect on survival within HBMEC monolayers.
Expression of vapDHi in Escherichia coli DH5α results in 
cell growth arrest
To test the hypothesis that VapDHi constituted the toxin,
and that VapXHi encoded the antitoxin portion of a TA
locus, both proteins were expressed in an E. coli back-
ground. E. coli does not contain a homologue of either
protein. Initially, the vapDHi gene, HI0450, was cloned
into the pTrcHisA vector (Invitrogen, Carlsbad, CA). This
resulted in vapDHi being under the control of the strong
Ptrc promoter, which is repressed for the most part until
induced by IPTG. This plasmid was designated pDD560.
Both the vector control, DH5α (pTrcHisA), and DH5αBMC Microbiology 2004, 4:30 http://www.biomedcentral.com/1471-2180/4/30
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(pDD560) were grown to mid-log phase in LB broth with
100 µg/ml ampicillin and aliquots were spread on LB agar
plates with 100 µg/ml ampicillin and 0.1 mM IPTG. Strain
DH5α (pTrcHisA) grew on the plates, but DH5α
(pDD560) did not, indicating that induction and overex-
pression of vapDHi was toxic to E. coli. The putative anti-
toxin VapXHi, was then cloned into the pTrcHisA vector.
No growth disruption occurred in DH5α with the overex-
pression of VapXHi alone. The vapXHi gene plus the lacIq
gene were then subcloned into the broad host range
mobilizable plasmid, pDD515, resulting in pDD672. This
strategy allowed the DH5α test strain to carry two compat-
ible plasmids, one which encoded the vapDHi  gene
(pDD560) and the other expressing the vapXHi antitoxin
gene (pDD672). Both genes were under the control of a
Ptrc  promoter and were therefore both repressed until
induced by IPTG. When both genes were induced with 0.1
mM IPTG on LB agar plates that contained 100 µg/ml
ampicillin and 10 µg/ml chloramphenicol in strain DH5α
(pDD560, pDD672), growth was restored. This indicated
that the concurrent expression of the vapXHi antitoxin with
the  vapDHi  toxin ameliorated the cell growth arrest
observed with expression of vapDHi alone, and that vapXHi
was necessary for this rescue.
Discussion
Mutation of the vapDHi allele in strains Rd and R3001
resulted in attenuation of survival within both HBMEC
and NCI-H292 monolayers, suggesting that in H. influen-
zae, the presence of a functional VapDHi facilitates persist-
ence within epithelial and endothelial cells. Mutants
invaded and survived in human cells at ≤ 60% of wild-
type levels. Although relatively modest, this level of
attenuation has been observed during the mutational
analysis of other Haemophilus virulence factors, such as
opacity-associated protein A as well as the high molecular
weight (HMW) proteins [11,16]. H. influenzae survival
within human cells is multifactorial, and our data indicate
that VapDHi contributes to this process. However, strain
Rd contains three other vap genes (vapAHi, vapBHi, and vap-
CHi), and it is possible that these Haemophilus vap genes act
synergistically, such that multiple mutations may result in
a more attenuated survival phenotype. Indeed, a recent
study has determined that a chromosomally-located
homologue of the VapBC locus acts as a toxin-antitoxin
module in the spirochete Leptospira interrogans [17]. It
would be interesting to characterize a Haemophilus strain
with mutations in all the vap genes.
Neither of the vapDHi mutants displayed differences in
adherence to the monolayers compared to the parent
strain, so the defect occurred after binding and affected
the organism's ability to persist inside or between cells.
Interestingly, the vapDHi mutants were not attenuated in
growth rate when compared to the parent strains, either in
bacteriological media or on the surface of human cell
monolayers. The observed survival attenuation of the
mutants could be transcomplemented with a full-length
allele from a clinical isolate, R3001, demonstrating that
the phenotype was due to the mutation in vapDHi and not
polar effects. A truncated allele from another clinical iso-
late, R2866, did not transcomplement the Rd vapDHi
strain, indicating that the truncated protein was not func-
tional in vivo. RT-PCR analysis confirmed that the full-
length vapDHi locus in Rd was transcribed during contact
with both epithelial and endothelial cells. VapDHi has also
been identified in the soluble fraction of strain Rd grown
in bacteriological media [10]. It remains to be seen if the
transcription of this locus increases upon contact with
human cells.
Results of a PCR survey on 59 randomly-chosen strains
showed that nearly all of the genetically highly heterolo-
gous NTHi commensal isolates surveyed (93%) carried a
full-length vapDHi allele on their chromosomes, suggest-
ing that maintenance of a functional vapDHi gene was ben-
eficial to survival in this niche (Table 2). Of the invasive
strains isolated from the blood or cerebrospinal fluid,
71% retained a full-length allele. Fifty percent of the iso-
lates from sputum, tracheal aspirates, and the middle ear
carried the full-length allele. Finally, all the encapsulated
strains tested contained a full-length allele. It must be
noted, however, that this analysis was not an exhaustive
study, since a limited number of strains were included.
Many clinical NTHi strains have previously been shown to
express various virulence factors that enhance adherence
and invasion into human cells which are not found in the
sequenced Rd strain [11,18-20]. The strains identified in
this PCR study that lack a functional vapDHi allele proba-
bly compensate for its loss with genes that are not found
in Rd, and these "extra genes" may well include other TA
loci.
The calculated molecular mass of the VapDHi protein in
Rd is approximately 10 kilodaltons, and small bacterial
proteins often form multimers. Full-length VapDHi subu-
nits exhibited strong homodimerization in a LexA-based
protein-protein interaction system, and this may indicate
that the subunits form higher-order multimers such as
homotrimers or homotetramers in vivo. However, the pro-
tein encoded by the truncated allele did not homodimer-
ize in the same system, further evidence of its loss of
function. Interestingly, the truncated subunit did interact
with full-length subunits in heterodimerization assays.
Further evidence of this heterodimerization in vivo was
that the expression of the truncated subunit in the wild-
type strain resulted in a dominant-negative effect on sur-
vival within HBMEC monolayers, the levels of which
mimicked the attenuation observed with the vapDHi muta-
tion. This was likely due to truncated subunits formingBMC Microbiology 2004, 4:30 http://www.biomedcentral.com/1471-2180/4/30
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hybrid complexes with full-length subunits and interfer-
ing with their structure and/or function, resulting in the
observed dominant-negative phenotype.
The activities of only a few toxins encoded by TA loci have
been elucidated thus far. Two specific targets of plasmid-
encoded toxins have been identified: CcdB of the F plas-
mid and ParE of plasmid RK2 inhibit DNA gyrase, and Kid
of plasmid R1 was previously thought to interact with
DnaB helicase, but has recently been shown to cleave cel-
lular mRNA [21-23]. The target and function of a toxin
from a chromosomally-encoded TA locus (relBE) was
determined to be cleavage of mRNA in the ribosomal A
site [24]. Strain Rd contains relBE homologues (HI0710
and HI0711) as well as a homologue of higA (host inhibi-
tion of growth antidote protein) from plasmid Rts1. The
higBA TA locus is unusual in that the toxin gene (higB)
exists upstream of the antidote protein (higA). Interest-
ingly, VapAHi of strain Rd is 29% identical and 53% simi-
lar to HigA.
While the data acquired in this study suggests that VapDHi
and VapXHi form a toxin-antitoxin pair, it is unusual to
find homologues of VapXHi only in H. influenzae and the
gonococcal plasmid. H. influenzae strains R2846 and
R2866 both have a truncated vapDHi toxin gene, and pos-
sess a vapXHi which is 100% identical to that gene in strain
Rd. Their respective genomes can be searched at http://
www.ncbi.nlm.nih.gov/sutils/genom_tree.cgi. Interest-
ingly, there are complete genome sequences available for
two isolates of H. pylori, N. meningitidis and Haemophilus
somnus, but only one strain of each has a homologue of
vapDHi. Thus, several features of the vapDHi/vapXHi gene
pair are unusual for a toxin-antitoxin locus.
Conclusions
Persistence of NTHi is important in the progression of dis-
ease caused by this organism. Many investigators have
previously reported the discovery of a number of viru-
lence factors associated with adherence, invasion and sur-
vival of NTHi inside human cells [1,3,4,16,18,25]. Here
we report a locus that is also involved in the pathogenesis
of nontypeable H. influenzae. Further studies are required
to fully characterize the mechanism of VapDHi function
and to define its role in the modulation of NTHi persist-
ence in human cells.
Methods
Bacterial strains, media and reagents
All H. influenzae strains used are listed in Table 2. H. influ-
enzae  was grown on chocolate agar (36 g Difco GC
medium, 10 g hemoglobin, 10 ml Difco Supplement B
(Becton Dickinson, Sparks, MD), 5,000 Units bacitracin
per liter) or supplemented BHI (sBHI) broth or agar (37 g
brain heart infusion media ± 15 g Bacto agar per liter
(Remel, Lenexa, KS) with 10 µg/ml  β-NAD, 10 µg/ml
heme-histidine, and 5 Units/ml bacitracin). Strains con-
taining the TSTE cassette [26] were grown on media with
15 µg/ml ribostamycin sulfate (CalBioChem, San Diego,
CA). Bacteria were diluted for plating with PBS-G (phos-
phate-buffered saline (pH 7.0) with 0.1% gelatin).
Escherichia coli strains used were DH5α, to clone frag-
ments of NTHi DNA; DD12, as the host strain in conjuga-
tions; and SU101 or SU202 as the reporter strains for the
homodimerization and heterodimerization assays,
respectively [14,15]. T4 bacteriophage was obtained from
the American Type Culture Collection (ATCC #11303).
Antibiotics and other chemicals were from Sigma-Aldrich
(St. Louis, MO). Restriction enzymes, deoxyribonucle-
otides, T4 DNA polymerase, and T4 DNA ligase were from
Promega (Madison, WI). Enzymes and other reagents for
PCR were from Eppendorf Scientific (Westbury, NY) and
Bioline (Canton, MA). Enzymes and reagents for reverse
transcriptase PCR (MasterAmp RT-PCR Kit) were from
Epicentre Technologies (Madison, WI). Oligonucleotide
primers were synthesized by Integrated DNA Technolo-
gies (Coralville, IA). DNA sequencing was performed by
the University of Missouri DNA Core Facility (Columbia,
MO), Davis Sequencing, LLC (Davis, CA), and the DNA
Core Facility at Seattle Biomedical Research Institute
(Seattle, WA). Plasmids were isolated using the Wizard SV
Plus Plasmid Miniprep kit, PCR products and restriction
digests were purified using the Wizard PCR Prep kit, and
total bacterial RNA was isolated using the SV Total RNA
Isolation System (Promega, Madison, WI).
Plasmids and conjugations
For transcomplementation, the 276 bp R3001 vapDHi
allele, along with 269 bp upstream and 227 bp down-
stream, was PCR-amplified using primers vapHI forward
5'-TATGTCTAGACAGTCGCTTCATAAGC-3' and vapHI
reverse 5'-CCATTCTAGATTTGAGGTTAAATATGG-3'.
Both primers included a XbaI site (underlined) and ampli-
fied Rd genome coordinates 472803 to 473572. The prod-
uct was sequenced and cloned both into the XbaI site of
pBluescript SK+ (creating plasmid pDD562) and into the
NheI site of pDD515, a mobilizable broad-host range vec-
tor that could be conjugally transferred into and stably
maintained in H. influenzae [12], creating plasmid
pDD564 (Table 1). Plasmid pDD564 was used for trans-
complementation of Rd vapDHi. The same primers were
used to PCR amplify the 135 bp truncated vapDHi allele
from strain R2866, the product of which was cloned into
the NheI site of pDD515, creating pDD594. The insert was
sequenced, then the plasmid was conjugally transferred
into both Rd vapDHi and wild-type Rd. Conjugations were
carried out as previously described [12]. For allelic
exchange, the plasmid pDD563 was constructed, which
consisted of pDD562 with an interruption of vapDHi by an
aminoglycoside phosphotransferase gene (aph (3')II).BMC Microbiology 2004, 4:30 http://www.biomedcentral.com/1471-2180/4/30
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Specifically, the 2184 bp BamHI  fragment from pTSTE
[26], which had been rendered blunt-ended with mung
bean nuclease, was inserted into the BsaBI site of vapDHi.
For the homodimerization assays, the plasmids pDD559
and pDD577 were derived from pSR658 and carried the
NTHi strain R3001 vapDHi allele or the NTHi strain R2866
vapDHiallele fused in-frame to the wild-type LexA DNA-
binding domain, respectively [27]. For the heterodimeri-
zation assays, the plasmid pDD561 derived from pSR659
was constructed, which consisted of the R3001 vapDHi
allele fused in-frame to the mutated LexA DNA-binding
domain.
Mutation of vapDHi
The vapDHi genes in Rd and strain R3001 were disrupted
by allelic exchange. Briefly, strains Rd and R3001 were
made competent using the M-IV media technique [28]
and pDD563 linearized with XmnI was used to transform
each strain. Transformants were selected on chocolate
agar supplemented with 15 µg/ml ribostamycin sulfate
(CalBioChem, San Diego, CA). The insertion in vapDHi
was confirmed by Southern blotting using a digoxygenin-
labeled denatured PCR fragment of vapDHi as the probe.
The orientation of the aminoglycoside phosphotrans-
ferase cassette was determined by PCR using a primer that
originated inside the aph (3')II gene and another that
flanked vapDHi. The resistance gene was found to be tran-
scribed in the opposite orientation of vapDHi  in both
strains.
Cell culture
Human brain microvascular endothelial cells (HBMECs)
were a gift from K. S. Kim [29]. Cells were passaged in col-
lagen-1 coated T-25 flasks and monolayers for invasion
assays were grown in 12-well collagen-1 coated BioCoat
plates (Becton Dickinson, Bedford, MA). HBMEC media
contained 760 ml RPMI 1640 with 25 mM HEPES and 2
mM L-glutamine, 100 ml heat-inactivated fetal calf serum,
10 ml each of 200 mM L-glutamine, 100× MEM non-
essential amino acid solution, 100× MEM vitamin solu-
tion, 100 mM MEM sodium pyruvate solution (Gibco,
Grand Island, NY), and 100 ml heat-inactivated NuSerum
V (Becton Dickinson, Bedford, MA) per liter. Media was
changed every two days and cells were passaged every 3–5
days. Monolayers were seeded at a density of ~2.0 × 105
cells per well and used 48 to 72 hours after seeding.
NCI-H292 human respiratory epithelial cells (ATCC cata-
logue # CRL-1848) were passaged in collagen-1 coated T-
25 flasks and monolayers for invasion assays were grown
to confluency in 12-well collagen-1 coated BioCoat plates
(Becton Dickinson, Bedford, MA). NCI-H292 media con-
sisted of 870 ml RPMI 1640 medium with 25 mM HEPES
and 2 mM L-glutamine, 10 ml of 100 mM MEM sodium
pyruvate solution, 10 ml of 7.5% w/v sodium bicarbonate
solution (Gibco, Grand Island, NY), 10 ml of 450 mg/ml
filter-sterilized glucose solution, and 100 ml heat-inacti-
vated fetal calf serum per liter. As above, media was
changed every two days and cells were passaged every 3–5
days. Monolayers were seeded at a density of ~2.5 × 105
cells per well and used 72 to 96 hours after seeding.
Invasion and survival assays
Gentamicin-resistance invasion and survival assays were
performed on HBMEC and NCI-H292 monolayers as pre-
viously described [5]. Briefly, the inoculum used was 1.0
– 5.0 × 106 CFU of H. influenzae in a volume of 1 ml per
well of a 12-well plate (an MOI of ≤ 10:1). After a 3 or 18
hour incubation in an atmosphere of 5% CO2 at 37°C,
each monolayer was extensively washed with Dulbecco's
PBS and 1.5 ml of media containing 100 µg/ml gen-
tamicin was added to each well. Following a subsequent
one hour incubation in the antibiotic, the wells were
again washed extensively, harvested with 1% saponin,
diluted in PBS-G and plated on chocolate or sBHI agar for
viable intracellular CFU/ml. To quantitate total cell-asso-
ciated bacteria (both intracellular and adherent), wells
were also harvested and plated after the first wash and
prior to gentamicin addition.
Methods for statistical analysis
Statistical analyses were performed using the statistical
analysis functions of Microsoft Excel (Microsoft Office
1997). For most comparisons of data, the Student's t-test
was used and P-values of <0.05 were considered to indi-
cate statistically significant differences.
Reverse transcriptase PCR (RT-PCR)
Total RNA was isolated using the SV Total RNA isolation
system (Promega, Madison, WI) from the wild type strain
Rd recovered from the media of 18-hour invasions of
either HBMEC (endothelial) or NCI-H292 (epithelial)
monolayers. Standard procedures were used, with the
modification that two separate DNAseI incubations were
performed instead of the single one recommended with
the kit. RT-PCR using the MasterAmp RT-PCR kit was then
performed as per the manufacturer's instructions (Epicen-
tre Technologies, Madison, WI). Negative controls of no
reverse transcriptase added to the RNA followed by tradi-
tional PCR using Biolase DNA polymerase (Bioline, Mad-
ison, WI) were used to ensure that both RNA preparations
were free of contaminating DNA. The primers for RT-PCR,
450 RT for (5'-CAGGCTTATACAGACATTGG-3') and 450
RT rev (5'-TCGTACCGACTGAGAAATCC-3') amplified a
153 bp internal portion of the vapDHi cDNA.
Protein-protein interaction assays
The vapDHi alleles from strains R3001 (full-length) and
R2866 (truncated) were amplified by PCR and fused in-
frame to the LexA DNA-binding domain (DBD) inBMC Microbiology 2004, 4:30 http://www.biomedcentral.com/1471-2180/4/30
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pSR658, resulting in pDD559 and pDD577, respectively,
and used to transform the reporter strain SU101 for
homodimerization assays [27]. Briefly, strain SU101 car-
ries a lacZ gene controlled by a wild-type LexA operator
site [14]. If a homodimer of two LexA DBD fusions was
formed, the complex could bind to the LexA operator
region and shut down transcription of lacZ, resulting in
diminished levels of beta-galactosidase. The vapDHi allele
from strain R3001 was also fused in-frame to the mutated
LexA DNA-binding domain in pSR659, creating pDD561.
The compatible plasmids pDD561 (full length vapDHi)
and pDD577 (truncated vapDHi) were both used to trans-
form the reporter strain SU202 for heterodimerization
assays. Strain SU202 [14] also has a lacZ gene controlled
by a LexA operator, but this operator site is engineered
such that only a mutated LexA DBD subunit (coded on
pSR659) can bind to one half-site, while a wild-type LexA
DBD subunit (coded on pSR658) can bind to the other
half-site. Consequently, only a heterodimer composed of
one mutated LexA DBD fusion subunit and one wild-type
LexA DBD fusion subunit could bind to this engineered
site and decrease transcription of lacZ in SU202. Three
independent beta-galactosidase assays were carried out in
triplicate as previously described [27].
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